The selection of a first-line chemotherapy drug to treat many types of cancer is often a clear-cut decision governed by standard-of-care protocols, but what drug should be used next if the first one fails? That’s where Georgia Institute of Technology researchers believe their new open source decision support tool could come in. Using machine learning to analyze RNA expression tied to…
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
A new method predicts the course of HPV-negative head and neck cancer after radiation chemotherapy. According to a recent article in the journal ‘Clinical Cancer Research’, five microRNAs (miRNAs) can provide the decisive data.
Using a new approach called 'reinforced learning', researchers have taught an artificial intelligence (AI) to responsibly choose the right amount of chemo- and radiotherapy for glioblastoma patients. The technique, which is insprired by behavioural psychology, has given the AI the ability to master the tightrope walk between effective tumor shrinkage and the medications' severe side effects.
‘Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline or taxane-based chemotherapy’, according to the latest clinical data published in The Breast. The paper, written by clinicians from the Berlin Oncology Center, Germany, revealed that 71% of women who took part on the study retained their hair as a result of using the Paxman Scalp Cooler. Scalp…
Blood is the juice of life, as while circulating through the body it delivers vital substances such as oxygen and nutrients to cells and tissues. Chemotherapy, radiotherapy and blood loss in general impoverish the system. A special kind of cells in the bone marrow, called hematopoietic stem cells (HSCs) is able to replenish the impoverished system by giving rise not only to red blood cells, but…
A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than those without the mutations. The same study also found that those with BRCA1 or BRCA2 had better survival rates with platinum-based chemotherapy, compared with similar patients…
A thin copper wire wrapped around a channel slightly thicker than a strand of hair could be the key to manufacturing a compact electronic device capable of counting white blood cells from the comfort of one’s home, a Kennesaw State University researcher says. Hoseon Lee, an assistant professor of electrical engineering in the Southern Polytechnic College of Engineering and Engineering…
Conventional chemotherapy in oncology is increasingly yielding to new procedures such as targeted therapy and immunotherapy. This results in changes for radiologists because new procedures require familiarisation with certain imaging to ensure that the treatment process is interpreted correctly.
A new optical imaging system developed at Columbia University uses red and near-infrared light to identify breast cancer patients who will respond to chemotherapy. The imaging system may be able to predict response to chemotherapy as early as two weeks after beginning treatment. Findings from a first pilot study of the new imaging system—a noninvasive method of measuring blood flow dynamics in…
Avoidance of side-effects of chemotherapy is particularly important in the elderly, but finding the balance between reduced toxicity and maximum effectiveness is not always easy. A trial carried out by the European Organisation for Research and Treatment of Cancer, published in The Lancet Oncology, shows that, in older patients with HER2 positive metastatic breast cancer (an aggressive breast…
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells’ chromatin. The study, which will be published in the Journal of Cell Biology, suggests that targeting this enzyme could make pancreatic cancer cells more vulnerable to existing therapies that currently have only limited effect…
Cornell researchers have taken a major step toward answering a key question in cancer research: Why is testicular cancer so responsive to chemotherapy, even after it metastasizes? Professional cyclist Lance Armstrong, for example, had testicular cancer that spread to his lung and brain, yet he made a full recovery after conventional chemotherapy. The key to such success appears to lie in the…
Early-stage colon cancer patients could benefit in the future from specific genetic tests that forecast their prognosis and help them make the right decision regarding chemotherapy.
The U.S. Food and Drug Administration has cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss (alopecia) during chemotherapy. This is the first cooling cap cleared by the agency for use in cancer patients with solid tumors.
Led by six globally-recognised experts in cancer care, the organisation known as CHILL, Cancer-related Hair Loss, International Leadership and Linkage, announced today an initiative to collect and track evidence-based patient information and clinical guidance. Data will be used to establish clinical best practices to ensure maximum effectiveness of scalp cooling to minimise chemotherapy-induced…
Paxman Coolers Limited announced today that The U.S. Food and Drug Administration (FDA) has cleared the company to market the Paxman Scalp Cooling System, a scalp cooling technology that was developed by a British family to reduce hair loss (alopecia) in breast cancer patients undergoing chemotherapy.
A pioneering scalp cooling treatment that prevents alopecia in early stage breast cancer patients undergoing chemotherapy will be showcased at the 15th St. Gallen International Breast Cancer Conference, Vienna.
One of the earliest widespread applications of precision medicine in cancer care is helping patients and physicians decide whether chemotherapy is needed, a new study finds.
Multidrug resistance (MDR) is the mechanism by which many cancers develop resistance to chemotherapy drugs, resulting in minimal cell death and the expansion of drug-resistant tumors. To address the problem of resistance, researchers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH) have developed nanoparticles that…
Small cell lung cancer is not usually detected until it is at an advanced stage, when metastases have already formed. Chemotherapy is very effective initially but, within a year, cancer recurs and this time does not respond to a course of chemotherapy. The research group headed by Gerhard Hamilton, University Department of Surgery at MedUni Vienna, has now managed to identify the reason for this…
A novel class of compounds developed by a University of Saskatchewan (U of S)-led research team could yield more effective and less toxic chemotherapy drugs to treat cancer. Team leader Jonathan Dimmock, a medicinal chemistry researcher in the U of S College of Pharmacy and Nutrition, explained their compounds work by interacting with thiols, naturally occurring chemicals that perform several…
Tumours kill off surrounding cells to make room to grow, according to new research from the University of Cambridge. Although the study was carried out using fruit flies, its findings suggest that drugs to prevent, rather than encourage, cell death might be effective at fighting cancer – contrary to how many of the current chemotherapy drugs work.
There’s apparently safety in numbers, even for cancer cells. New research in mice suggests that cancer cells rarely form metastatic tumors on their own, preferring to travel in groups since collaboration seems to increase their collective chances of survival, according to researchers at Johns Hopkins.
Researchers compared an immunotherapy and a chemotherapy drug in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy. They found that nivolumab improved overall survival and was generally well tolerated. The results are significant because options for patients whose lung cancer progresses after initial treatment are…